Skip to main content
Premium Trial:

Request an Annual Quote

Synthetic Biology Firm Evonetix Raises $12.3M

NEW YORK (GenomeWeb) – Synthetic biology firm Evonetix announced today that it has closed a $12.3 million financing round.

The financing was co-led by Data Collective and Draper Esprit, and included Morningside Group along with existing investors Providence Investment Company, Cambridge Consultants, Rising Tide Fund, and Civilization Ventures. Evonetix was spun out of Cambridge Consultants in 2016.

The firm said it will use the funding to further develop its core gene synthesis platform, which uses an addressable silicon array to direct the synthesis of DNA at many sites in parallel, followed by an error-detection process to allow the assembly of high-fidelity DNA at scale.

"Evonetix's platform offers the prospect of synthesizing DNA sequences accurately without limitation of size," Draper Esprit Partner Vishal Gulati said in a statement. "This is the superpower that could transform the world of synthetic biology and allow us to engineer next-generation medicines and better versions of products we use every day."

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.